Targeting RNA Modifications for Drug Development: The Role of Epitranscriptomics in Pharmacology
Article Sidebar
Page Numbers:
97-124
Published:
Mar 23, 2026
Digital Object Identifier:
10.58578/ajbmbr.v3i1.9351
Save this to:
Article Metrics:
Viewed: 167 times
Downloaded: 124 times
Article can trace at:
Author Fee:
Free Publication Fees for Foreign Researchers (USD 0.00)
Check for article on SINTA:
LYAS Publisher cordially invites qualified professionals to serve as Editors or Reviewers. Your expertise will make an important contribution to maintaining and strengthening the academic quality of our publications. Interested applicants are kindly requested to complete the application form at the following link: Editors & Reviewers
Connected Papers:
Please feel free to contact us if you need any further information about the submission process or if you have any additional questions.
Authors:Nafiu Sani Barau1, Tsutsu Terva Collins2, Aliyu Muqaddas Abdulkadir3
Copyright :Authors retain copyright and grant the journal right of first publication.
Main Article Content
Abstract
Epitranscriptomics has emerged as an additional regulatory layer of gene expression mediated by chemical modifications on RNA molecules, with important implications for cellular function and disease. This review synthesizes recent advances in epitranscriptomic research, focusing on major RNA modifications, including N⁶-methyladenosine, pseudouridine, and 5-methylcytosine, and their mechanistic roles in regulating RNA stability, splicing, localization, and translational efficiency through the coordinated actions of writers, erasers, and readers. It further examines the dynamic regulation of RNA modifications under pathological stress conditions and highlights their contribution to disease pathogenesis, particularly in cancer, metabolic disorders, and neurological diseases. In addition, the review discusses emerging pharmacological strategies targeting epitranscriptomic regulators, including small-molecule inhibitors and RNA-based therapeutic approaches. The evidence collectively indicates that RNA modifications represent promising therapeutic targets, while also underscoring persistent challenges related to target specificity, delivery efficiency, and off-target effects. The review concludes that epitranscriptomics constitutes a rapidly evolving frontier in drug discovery and precision pharmacology by expanding current understanding of disease mechanisms and offering new directions for therapeutic innovation.
Downloads
Download data is not yet available.
Article Details
How to Cite
Barau, N. S., Collins, T. T., & Abdulkadir, A. M. (2026). Targeting RNA Modifications for Drug Development: The Role of Epitranscriptomics in Pharmacology. African Journal of Biochemistry and Molecular Biology Research, 3(1), 97-124. https://doi.org/10.58578/ajbmbr.v3i1.9351
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
References
Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. J., Verdine, V., Cox, D. B. T., Kellner, M. J., Regev, A., Lander, E. S., Voytas, D. F., Ting, A. Y., & Zhang, F. (2017). RNA targeting with CRISPR-Cas13. Nature, 550(7675), 280–284. https://doi.org/10.1038/nature24049
Adachi, H., De Zoysa, M. D., Yu, Y.-T., & Tomita, K. (2023). Targeted pseudouridylation: An approach for suppressing nonsense mutations in disease genes. Molecular Cell, 83(4), 637–651.e9. https://doi.org/10.1016/j.molcel.2023.01.009
Artika, I. M., Arianti, R., Demény, M. Á., & Kristóf, E. K. (2025). RNA modifications and their role in gene expression. Frontiers in Molecular Biosciences, 12, 1537861. https://doi.org/10.3389/fmolb.2025.1537861
Arzumanian, V. A., Kuleshov, M. V., & Lobanov, A. V. (2022). The role of RNA modifications in health and disease. International Journal of Molecular Sciences, 23(5), 2565.
Bai, X., Liu, Y., & Zhang, Y. (2023). RNA modifications and cancer: Emerging connections and therapeutic implications. Journal of Cancer Research and Clinical Oncology, 149(4), 1203–1218.
Barbieri, I., Kouzarides, T., & Schaefer, M. (2020). Role of RNA modifications in cancer. Nature Reviews Cancer, 20(6), 303–322.
Barrangou, R., & Doudna, J. A. (2016). Applications of CRISPR technologies in research and beyond. Nature Biotechnology, 34, 933–941. https://doi.org/10.1038/nbt.3659
Borchardt, E. K., Martinez, N. M., & Gilbert, W. V. (2020). Regulation and function of RNA pseudouridylation in human cells. Annual Review of Genetics, 54, 309–336.
Cao, K., Du, Y., Bao, X., Han, M., Su, R., Pang, J., Liu, S., Shi, Z., Yan, F., & Feng, S. (2022). Glutathione-bioimprinted nanoparticles targeting of N6-methyladenosine FTO demethylase as a strategy against leukemic stem cells. Small, 18(13), e2106558. https://doi.org/10.1002/smll.202106558
Chang, R., Zhu, S., Peng, J., Lang, Z., Zhou, X., Liao, H., Zou, J., Zeng, P., & Tan, S. (2023). The hippocampal FTO-BDNF-TrkB pathway is required for novel object recognition memory reconsolidation in mice. Translational Psychiatry, 13, 1–8.
Chao, Y., Li, X., & Wang, X. (2021). METTL3 regulates T cell differentiation and proliferation through m6A modification. Frontiers in Immunology, 12, 630002.
Chen, B., Ye, F., Yu, L., Jia, G., Huang, X., Zhang, X., Peng, S., Chen, K., Wang, M., Gong, S., Zhang, R., Yin, J., Li, H., Yang, Y., Liu, H., Zhang, J., Zhang, H., Zhang, A., Luo, C., ... Yang, C.-G. (2012). Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor. Journal of the American Chemical Society, 134(43), 17963–17971. https://doi.org/10.1021/ja3064149
Chen, L., Li, J., Wang, L., Xu, Y., Zhang, Y., Zhao, Y., Yang, H., & Xu, Y. (2022). METTL3-mediated m6A modification stabilizes TERRA and maintains telomere stability. Nucleic Acids Research, 50(20), 11619–11634.
Chen, L., Wang, Y., & Zhao, X. (2024). Functional roles of RNA modifications in cancer progression and therapy. Cancer Letters, 566, 216256.
Chen, Y., Wang, W., Zhang, W., He, M., Li, Y., Qu, G., & Tong, J. (2023). Emerging roles of biological m6A proteins in regulating virus infection: A review. International Journal of Biological Macromolecules, 253, 126934.
Chen, Y., Zhou, Z., Chen, Y., & Chen, D. (2024). Reading the m6A-encoded epitranscriptomic information in development and diseases. Cell & Bioscience, 14(1), 124.
Cheng, J., Ma, J., Sun, B., Gao, Y., Zhou, Y., Hu, H., ... Wang, H. (2021). RNA 5-methylcytosine methyltransferases: Functions, regulation, and clinical relevance. Frontiers in Cell and Developmental Biology, 9, 640543.
Cox, D. B. T., Gootenberg, J. S., Abudayyeh, O. O., Franklin, B., Kellner, M. J., Joung, J., & Zhang, F. (2017). RNA editing with CRISPR-Cas13. Science, 358(6366), 1019–1027. https://doi.org/10.1126/science.aaq0180
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018). RNA-targeted therapeutics. Cell Metabolism, 27(4), 714–739.
Cui, Q., Shi, H., Ye, P., Li, L., Qu, Q., Sun, G., Sun, G., Lu, Z., Huang, Y., Yang, C.-G., Riggs, A. D., He, C., & Shi, Y. (2017). m6A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. Cell Reports, 18(11), 2622–2634.
Du, K., Zhang, Z., Zeng, Z., Tang, J., Lee, T., & Sun, T. (2021). Distinct roles of Fto and Mettl3 in controlling development of the cerebral cortex through transcriptional and translational regulations. Cell Death & Disease, 12(7), 700.
Du, Y., Zhao, Z., & Li, Q. (2024). METTL14 promotes acute myeloid leukemia progression via m6A modification of MYB and MYC. Leukemia, 38(2), 456–467.
Eisenberg, E., & Levanon, E. Y. (2018). A-to-I RNA editing: Immune protector and transcriptome diversifier. Nature Reviews Genetics, 19(8), 473–490.
Esteve-Puig, R., Clot, G., & Guillaumet-Adkins, A. (2020). DNA methylation: Beyond CpG islands. Nature Reviews Genetics, 21(8), 492–492.
Fang, M., Ye, L., Zhu, Y., Huang, L., & Xu, S. (2025). M6A demethylase ALKBH5 in human diseases: From structure to mechanisms. Biomolecules, 15(2), 157. https://doi.org/10.3390/biom15020157
Feng, G., Wu, Y., Hu, Y., Shuai, W., Yang, X., Li, Y., Ouyang, L., & Wang, G. (2024). Small molecule inhibitors targeting m6A regulators. Journal of Hematology & Oncology, 17(1), 30.
Fiorentino, F., Menna, M., Rotili, D., Valente, S., & Mai, A. (2023). METTL3 from target validation to the first small-molecule inhibitors: A medicinal chemistry journey. Journal of Medicinal Chemistry, 66(3), 1654–1677. https://doi.org/10.1021/acs.jmedchem.2c01601
Gao, Z., Zha, X., Li, M., Xia, X., & Wang, S. (2024). Insights into the m6A demethylases FTO and ALKBH5: Structural, biological function, and inhibitor development. Cell & Bioscience, 14(1), 108.
Gu, X., Wang, L., Zhou, Y., Hu, X., Zhou, J., & Yan, C. (2021). NOP2/NSUN family: Key regulators in RNA methylation and cancer. Frontiers in Oncology, 11, 614640.
Guan, J. (2024). Oncogenic role of METTL3-mediated m6A modification in cancer. Molecular Cancer, 23(1), 12.
Guo, Q., Shi, X., & Wang, X. (2021). RNA and liquid-liquid phase separation. Noncoding RNA Research, 6(2), 92–99.
Han, D., Liu, J., Chen, C., Dong, L., Liu, Y., Chang, R., & He, C. (2023). Anti-tumour immunity controlled through mRNA m5C methylation and YBX1. Nature, 615(7953), 564–571.
Höfler, S., & Duss, O. (2024). Interconnections between m6A RNA modification, RNA structure, and protein-RNA complex assembly. Life Science Alliance, 7(1), e202302240. https://doi.org/10.26508/lsa.202302240
Huang, H., Weng, H., & Chen, J. (2020). m6A modification in coding and non-coding RNAs: Roles and therapeutic implications in cancer. Cancer Cell, 37(3), 270–288.
Huang, W., Qi, C., & Zhang, H. (2019). The emerging role of N1-methyladenosine (m1A) in post-transcriptional regulation. Cell & Bioscience, 9(1), 1–11.
Huang, Y., Su, R., Sheng, Y., Dong, L., Dong, Z., Xu, H., Ni, T., Zhang, Z. S., Zhang, T., Li, C., Han, L., Zhu, Z., Lian, F., Wei, J., Deng, Q., Wang, Y., Wunderlich, M., Gao, Z., Pan, G., ... Yang, C.-G. (2019). Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell, 35(4), 677–691.e10. https://doi.org/10.1016/j.ccell.2019.03.006
Jurkowska, R. Z. (2024). Chromatin regulation by histone-modifying complexes. Trends in Biochemical Sciences, 49(1), 1–14.
Katrekar, D., Yen, J., Xiang, Y., & Mali, P. (2022). Efficient in vitro and in vivo RNA editing via recruitment of endogenous ADARs using circular guide RNAs. Nature Biotechnology, 40(6), 938–945. https://doi.org/10.1038/s41587-021-01171-4
Lai, G. Q., Li, Y., Zhu, H., Zhang, T., Gao, J., Zhou, H., & Yang, C.-G. (2024). A covalent compound selectively inhibits RNA demethylase ALKBH5 rather than FTO. RSC Chemical Biology, 5(4), 335–343.
Li, M., Cheng, W., Zhang, L., Zhou, C., Peng, X., Yu, S., & Zhang, W. (2022). Novel roles of RNA m6A methylation regulators in the occurrence of Alzheimer’s disease and the subtype classification. International Journal of Molecular Sciences, 23(18), 10766.
Li, T., Hu, P., & Chen, X. (2021). Silencing METTL3 attenuates cardiac fibrosis after myocardial infarction. FASEB Journal, 35(2), e21257.
Li, W., Sun, R., & Zhou, X. (2025). METTL3-mediated m6A methylation promotes EMT and metastasis in cancer. Journal of Experimental & Clinical Cancer Research, 44(1), 15.
Li, Y., Bedi, R. K., Nai, F., von Roten, V., Dolbois, A., Zalešák, F., Nachawati, R., Huang, D., & Caflisch, A. (2022). Structure-based design of ligands of the m6A-RNA reader YTHDC1. European Journal of Medicinal Chemistry Reports, 5, 100057.
Liang, Y., Han, H., Liu, L., Duan, T., Zhao, Y., Xu, Q., & Chen, Y. (2024). m6A reader proteins in RNA metabolism, disease, and therapeutics. Pharmacology & Therapeutics, 250, 108478.
Liu, L., Qiu, Y., Suo, Y., Tong, S., Wang, Y., Zhang, X., Chen, L., Huang, Y., Zhou, H., Zhou, H., Dong, Z., & Yang, C.-G. (2024). Discovery of a potent PROTAC degrader for RNA demethylase FTO as antileukemic therapy. Acta Pharmaceutica Sinica B, 14(12), 5382–5392.
Liu, M., Wang, Y., Zhang, Y., Hu, D., Tang, L., Zhou, B., & Yang, L. (2025). Landscape of small nucleic acid therapeutics: Moving from the bench to the clinic as next-generation medicines. Signal Transduction and Targeted Therapy, 10(1), 73. https://doi.org/10.1038/s41392-024-02112-8
Liu, X. M., Zhou, J., Mao, Y., Ji, Q., Qian, S. B., & Shi, H. (2019). Programmable RNA N6-methyladenosine editing by CRISPR-Cas9 conjugates. Nature Chemical Biology, 15(9), 865–871. https://doi.org/10.1038/s41589-019-0327-1
Liu, Y., Li, X., Zhou, B., Zhang, X., & Zhao, Y. (2024). The role of pseudouridylation in mRNA translation and stability. RNA Biology, 21(1), 1–14.
Liu, Y., Wang, J., Zhang, Z., Chen, H., & Xu, Y. (2025). N6-methyladenosine modification regulates oxidative stress and inflammation in intervertebral disc degeneration. Frontiers in Cell and Developmental Biology, 13, 1547265.
Liu, Z., Gao, L., Cheng, L., Zhang, Y., Chen, L., & Zhu, W. (2023). The roles of N6-methyladenosine and its target regulatory noncoding RNAs in tumors: Classification, mechanisms, and potential therapeutic implications. Experimental & Molecular Medicine, 55, 487–501.
Lv, J., Zhang, Y., Gao, Y., Xu, S., Zhang, H., & Deng, J. (2021). METTL3-mediated m6A modification regulates Treg cell stability and suppressive function. Journal of Autoimmunity, 117, 102576.
Martin, R. L., Heifetz, A., Bodkin, M. J., & Townsend-Nicholson, A. (2024). High-throughput structure-based drug design (HT-SBDD) using drug docking, fragment molecular orbital calculations, and molecular dynamic techniques. In Methods in Molecular Biology (Vol. 2716, pp. 293–306). Springer. https://doi.org/10.1007/978-1-0716-3449-3_13
Mendel, M., Chen, K. M., Homolka, D., Gos, P., Pandey, R. R., McCarthy, A. A., & Pillai, R. S. (2021). Splice site m6A methylation prevents binding of U2AF35 to inhibit RNA splicing. Nature, 598(7882), 332–336.
Nossent, A. Y., Liu, L., Hansen, T. B., & Kjems, J. (2023). The emerging role of m6A in cardiovascular biology and disease. Cardiovascular Research, 119(2), 326–341.
Ouyang, H., Chen, Z., & Wang, J. (2024). METTL3-mediated m6A methylation enhances metastasis via stabilization of ZEB1 and SNAIL mRNAs. Cell Death & Disease, 15, 142.
Padda, I. S., Kalra, I., & Kalagara, R. (2024). Small interfering RNA therapeutics. StatPearls Publishing.
Paramasivam, A., Priyadharsini, J. V., & Raghunandhakumar, S. (2020). Implications of m6A modification in autoimmune disorders. Molecular Biology Reports, 47, 9267–9275.
Park, C. W., Lee, S. M., & Yoon, K. J. (2020). Epitranscriptomic regulation of transcriptome plasticity in development and diseases of the brain. BMB Reports, 53(11), 551–564.
Pickar-Oliver, A., & Gersbach, C. A. (2019). The next generation of CRISPR-Cas technologies and applications. Nature Reviews Molecular Cell Biology, 20, 490–507.
Qin, Y., Liu, X., Pan, Y., & Liu, J. (2022). The m6A-modified circular RNAs in cancer progression: Roles, mechanisms, and potential applications. Frontiers in Oncology, 12, 891276.
Qui, Y., Xu, Z., Zhang, X., & Zhou, L. (2023). Epitranscriptomic regulation of gene expression: Focus on m6A and m5C. Cellular and Molecular Life Sciences, 80(1), 1–21.
Rau, K., Rentmeister, A., & Reimann, R. (2019). Sequence-specific m6A demethylation in RNA by FTO fused to RCas9. RNA, 25(10), 1311–1323.
Shen, D., Wang, B., Gao, Y., Zhao, L., Bi, Y., Zhang, J., Wang, N., Kang, H., Pang, J., Liu, Y., Pang, L., Chen, Z.-S., Zheng, Y.-C., & Liu, H.-M. (2022). Detailed resume of RNA m6A demethylases. Acta Pharmaceutica Sinica B, 12(5), 2193–2205. https://doi.org/10.1016/j.apsb.2022.01.003
Shi, H., Wei, J., & He, C. (2020). Where, when, and how: Context-dependent functions of RNA methylation writers, readers, and erasers. Molecular Cell, 78(1), 1–16.
Song, H., Zhang, J., Liu, B., Xu, J., Cai, B., Yang, H., Straube, J., Yu, X., & Ma, T. (2022). Biological roles of RNA m5C modification and its implications in cancer immunotherapy. Biomarker Research, 10(1), 15.
Song, J., Zong, J., Yu, Y.-T., & Li, X. (2023). CRISPR-free, programmable RNA pseudouridylation to suppress premature termination codons. Molecular Cell, 83(1), 139–155.e9. https://doi.org/10.1016/j.molcel.2022.11.011
Su, R., Dong, L., Li, Y., Gao, M., Han, L., Wunderlich, M., Deng, X., Li, H., Huang, Y., Gao, L., Li, C., Zhao, Z., Robinson, S., Tan, B., Qing, Y., Qin, X., Prince, E., Xie, J., Qin, H., Li, W., ... Chen, J. (2020). Targeting FTO suppresses cancer stem cell maintenance and immune evasion. Cancer Cell, 38(1), 79–96.e11.
Sun, T., Wu, R., & Ming, L. (2023). The role of m6A RNA methylation in cancer metabolism. Molecular Cancer, 22(1), 1–16.
Sweef, M., Alshahrani, M., & Wang, W. (2024). N1-methyladenosine (m1A) modification in human diseases. Frontiers in Molecular Biosciences, 11, 1304567.
Thalhammer, A., Bencokova, Z., Poole, R., Loenarz, C., Adam, J., O'Flaherty, L., & Pollard, P. J. (2011). Human AlkB homologue 5 is a nuclear 2-oxoglutarate dependent oxygenase and a direct target of hypoxia-inducible factor-1α (HIF-1α). PLoS ONE, 6(1), e16210.
Tooley, J. G., Catlin, J. P., & Schaner Tooley, C. E. (2023). METTLing in stem cell and cancer biology. Stem Cell Reviews and Reports, 19(1), 76–91. https://doi.org/10.1007/s12015-022-10444-7
U.S. Food and Drug Administration. (2018, August 14). New class of drugs fulfills promise of RNA-based medicine. https://www.fda.gov/drugs/spotlight-cder-science/new-class-drugs-fulfills-promise-rna-based-medicine
Wang, J., Yan, S., Lu, H., Wang, S., Xu, D., & Xu, Z. (2021). Role of m6A RNA methylation in immunoregulation and autoimmunity. Frontiers in Cell and Developmental Biology, 9, 757677.
Wang, X., Li, Z., & Zhang, Y. (2024). m1A RNA modification: Mechanisms, functions, and disease relevance. RNA Biology, 21(2), 200–214.
Wang, X., Ma, X., Chen, S., Fan, M., Jin, C., Chen, Y., Wang, S., Wang, Z., Meng, F., Zhang, C., & Yang, L. (2024). Harnessing m1A modification: A new frontier in cancer immunotherapy. Frontiers in Immunology, 15, 1517604. https://doi.org/10.3389/fimmu.2024.1517604
Wang, X., Zhao, B. S., Roundtree, I. A., Lu, Z., Han, D., Ma, H., & He, C. (2015). N6-methyladenosine modulates messenger RNA translation efficiency. Cell, 161(6), 1388–1399.
Wen, J., Lv, R., Ma, H., Shen, H., He, C., Wang, J., & Shi, Y. (2024). YTHDF1 regulates dendritic cell-mediated immune response via m6A-dependent translation of immune transcripts. Nature Communications, 15, 1124.
Wilkinson, A., Ji, D., Papa, F., & Schaefer, M. (2022). The dynamic life of m6A RNA modification. Nature Reviews Genetics, 23(8), 499–512.
Wilkinson, J., Thalhammer, A., Loenarz, C., & Schofield, C. J. (2021). Regulation of the ALKBH5 RNA demethylase in hypoxia. Biochemical Journal, 478(7), 1483–1501.
Wilson, C., Chen, P. J., Miao, Z., & Liu, D. R. (2020). Programmable m6A modification of cellular RNAs with a Cas13-directed methyltransferase. Nature Biotechnology, 38(12), 1431–1440. https://doi.org/10.1038/s41587-020-0572-6
Wong, J. M., & Eirin-Lopez, J. M. (2021). Evolution of methyltransferase-like (METTL) proteins in Metazoa: A complex gene family involved in epitranscriptomic regulation and other epigenetic processes. Molecular Biology and Evolution, 38(12), 5309–5327.
Xia, Z., Tang, H., Wang, S., He, S., Zhang, L., & Chen, S. (2021). Epitranscriptomic editing of the RNA N6-methyladenosine modification by dCasRx conjugated methyltransferase and demethylase. Nucleic Acids Research, 49(13), 7361–7374. https://doi.org/10.1093/nar/gkab517
Xie, G., Wu, X.-N., Ling, Y., Rui, Y., Wu, D., Zhou, J., et al. (2022). A novel inhibitor of N6-methyladenosine demethylase FTO induces mRNA methylation and shows anti-cancer activities. Acta Pharmaceutica Sinica B, 12(2), 853–866. https://doi.org/10.1016/j.apsb.2021.08.028
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023). Recent advances in targeting the “undruggable” proteins: From drug discovery to clinical trials. Signal Transduction and Targeted Therapy, 8(1), 335. https://doi.org/10.1038/s41392-023-01589-z
Xiong, X., Li, X., & Yi, C. (2022). N1-methyladenosine methylome in eukaryotic messenger RNA and its biological implications. Nature Structural & Molecular Biology, 29(4), 271–280.
Xu, Y., Zhang, Y., & Zhang, J. (2022). Epigenetic regulation by histone modifications in cancer. Nature Reviews Cancer, 22(11), 671–686.
Xue, C., Zhao, Y., & Li, L. (2022). RNA methylation in plant and human biology. RNA Biology, 19(5), 569–583.
Yang, Y., Hsu, P. J., Chen, Y. S., & Yang, Y. G. (2022). Dynamic transcriptomic m6A decoration: Writers, erasers, readers and functions in RNA metabolism. Cell Research, 32(5), 499–516.
Yang, Y., Lu, Y., Wang, Y., Wen, X., Qi, C., Piao, W., & Jin, H. (2024). Current progress in strategies to profile transcriptomic m6A modifications. Frontiers in Cell and Developmental Biology, 12, 1392159.
Yao, Y., Yang, Y., Guo, W., Xu, L., You, M., Zhang, Y., & Han, J. (2021). METTL3-dependent m6A modification programs dendritic cell activation. Nature Communications, 12, 5826.
Ying, X., Jiang, X., Zhang, H., Liu, B., Huang, Y., & Zhang, H. (2020). Programmable N6-methyladenosine modification of CDCP1 mRNA by RCas9-methyltransferase-like 3 conjugates promotes bladder cancer development. Molecular Cancer, 19(1), 1–6.
Zhang, C., Samanta, D., Lu, H., Bullen, J. W., Zhang, H., Chen, I., & Semenza, G. L. (2016). Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA. Proceedings of the National Academy of Sciences of the United States of America, 113(14), E2047–E2056. https://doi.org/10.1073/pnas.1602883113
Zhang, J., Tong, L., Liu, Y., Li, X., Wang, J., Lin, R., Zhou, Z., Chen, Y., Chen, Y., Liu, Y., & Chen, D. (2023). The regulatory role of m6A modification in the maintenance and differentiation of embryonic stem cells. Genes & Diseases, 11(5), 101199.
Zhang, X., Li, H., & Chen, Y. (2021). m5C modification in RNA: Mechanisms and implications in human disease. Frontiers in Genetics, 12, 730682.
Zhang, X., Li, J., Zhou, X., Liu, Y., Wang, Z., & Li, L. (2024). METTL3 in immune regulation and autoimmune disease pathogenesis. Autoimmunity Reviews, 23, 103453.
Zhao, B. S., Wang, X., Beadell, A. V., Lu, Z., Shi, H., Kuuspalu, A., Ho, R. K., & He, C. (2017). m6A-dependent maternal mRNA clearance facilitates zebrafish maternal-to-zygotic transition. Nature, 542(7642), 475–478. https://doi.org/10.1038/nature21355
Zhao, F., Xu, Y., Gao, S., Qin, L., Austria, Q., Siedlak, S. L., Pajdzik, K., Dai, Q., He, C., Wang, W., O'Donnell, J. M., Tang, B., & Zhu, X. (2021). METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer’s disease through aberrant cell cycle events. Molecular Neurodegeneration, 16(1), 70. https://doi.org/10.1186/s13024-021-00484-x
Zhao, Y., Dunker, W., Yu, Y.-T., & Karijolich, J. (2018). The role of noncoding RNA pseudouridylation in nuclear gene expression events. Frontiers in Bioengineering and Biotechnology, 6, 8. https://doi.org/10.3389/fbioe.2018.00008
Zhao, Y., Wang, X., & Li, X. (2025). Pseudouridine and its functional implications in RNA biology. Trends in Biochemical Sciences, 50(1), 12–25.
Zou, J., Guo, Y., Zhao, Y., Pan, W., Xu, J., & Su, S. (2024). N6-methyladenosine modification of SARS-CoV-2 RNA facilitates immune evasion and viral replication. Cell Reports, 42, 113452.
Adachi, H., De Zoysa, M. D., Yu, Y.-T., & Tomita, K. (2023). Targeted pseudouridylation: An approach for suppressing nonsense mutations in disease genes. Molecular Cell, 83(4), 637–651.e9. https://doi.org/10.1016/j.molcel.2023.01.009
Artika, I. M., Arianti, R., Demény, M. Á., & Kristóf, E. K. (2025). RNA modifications and their role in gene expression. Frontiers in Molecular Biosciences, 12, 1537861. https://doi.org/10.3389/fmolb.2025.1537861
Arzumanian, V. A., Kuleshov, M. V., & Lobanov, A. V. (2022). The role of RNA modifications in health and disease. International Journal of Molecular Sciences, 23(5), 2565.
Bai, X., Liu, Y., & Zhang, Y. (2023). RNA modifications and cancer: Emerging connections and therapeutic implications. Journal of Cancer Research and Clinical Oncology, 149(4), 1203–1218.
Barbieri, I., Kouzarides, T., & Schaefer, M. (2020). Role of RNA modifications in cancer. Nature Reviews Cancer, 20(6), 303–322.
Barrangou, R., & Doudna, J. A. (2016). Applications of CRISPR technologies in research and beyond. Nature Biotechnology, 34, 933–941. https://doi.org/10.1038/nbt.3659
Borchardt, E. K., Martinez, N. M., & Gilbert, W. V. (2020). Regulation and function of RNA pseudouridylation in human cells. Annual Review of Genetics, 54, 309–336.
Cao, K., Du, Y., Bao, X., Han, M., Su, R., Pang, J., Liu, S., Shi, Z., Yan, F., & Feng, S. (2022). Glutathione-bioimprinted nanoparticles targeting of N6-methyladenosine FTO demethylase as a strategy against leukemic stem cells. Small, 18(13), e2106558. https://doi.org/10.1002/smll.202106558
Chang, R., Zhu, S., Peng, J., Lang, Z., Zhou, X., Liao, H., Zou, J., Zeng, P., & Tan, S. (2023). The hippocampal FTO-BDNF-TrkB pathway is required for novel object recognition memory reconsolidation in mice. Translational Psychiatry, 13, 1–8.
Chao, Y., Li, X., & Wang, X. (2021). METTL3 regulates T cell differentiation and proliferation through m6A modification. Frontiers in Immunology, 12, 630002.
Chen, B., Ye, F., Yu, L., Jia, G., Huang, X., Zhang, X., Peng, S., Chen, K., Wang, M., Gong, S., Zhang, R., Yin, J., Li, H., Yang, Y., Liu, H., Zhang, J., Zhang, H., Zhang, A., Luo, C., ... Yang, C.-G. (2012). Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor. Journal of the American Chemical Society, 134(43), 17963–17971. https://doi.org/10.1021/ja3064149
Chen, L., Li, J., Wang, L., Xu, Y., Zhang, Y., Zhao, Y., Yang, H., & Xu, Y. (2022). METTL3-mediated m6A modification stabilizes TERRA and maintains telomere stability. Nucleic Acids Research, 50(20), 11619–11634.
Chen, L., Wang, Y., & Zhao, X. (2024). Functional roles of RNA modifications in cancer progression and therapy. Cancer Letters, 566, 216256.
Chen, Y., Wang, W., Zhang, W., He, M., Li, Y., Qu, G., & Tong, J. (2023). Emerging roles of biological m6A proteins in regulating virus infection: A review. International Journal of Biological Macromolecules, 253, 126934.
Chen, Y., Zhou, Z., Chen, Y., & Chen, D. (2024). Reading the m6A-encoded epitranscriptomic information in development and diseases. Cell & Bioscience, 14(1), 124.
Cheng, J., Ma, J., Sun, B., Gao, Y., Zhou, Y., Hu, H., ... Wang, H. (2021). RNA 5-methylcytosine methyltransferases: Functions, regulation, and clinical relevance. Frontiers in Cell and Developmental Biology, 9, 640543.
Cox, D. B. T., Gootenberg, J. S., Abudayyeh, O. O., Franklin, B., Kellner, M. J., Joung, J., & Zhang, F. (2017). RNA editing with CRISPR-Cas13. Science, 358(6366), 1019–1027. https://doi.org/10.1126/science.aaq0180
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018). RNA-targeted therapeutics. Cell Metabolism, 27(4), 714–739.
Cui, Q., Shi, H., Ye, P., Li, L., Qu, Q., Sun, G., Sun, G., Lu, Z., Huang, Y., Yang, C.-G., Riggs, A. D., He, C., & Shi, Y. (2017). m6A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. Cell Reports, 18(11), 2622–2634.
Du, K., Zhang, Z., Zeng, Z., Tang, J., Lee, T., & Sun, T. (2021). Distinct roles of Fto and Mettl3 in controlling development of the cerebral cortex through transcriptional and translational regulations. Cell Death & Disease, 12(7), 700.
Du, Y., Zhao, Z., & Li, Q. (2024). METTL14 promotes acute myeloid leukemia progression via m6A modification of MYB and MYC. Leukemia, 38(2), 456–467.
Eisenberg, E., & Levanon, E. Y. (2018). A-to-I RNA editing: Immune protector and transcriptome diversifier. Nature Reviews Genetics, 19(8), 473–490.
Esteve-Puig, R., Clot, G., & Guillaumet-Adkins, A. (2020). DNA methylation: Beyond CpG islands. Nature Reviews Genetics, 21(8), 492–492.
Fang, M., Ye, L., Zhu, Y., Huang, L., & Xu, S. (2025). M6A demethylase ALKBH5 in human diseases: From structure to mechanisms. Biomolecules, 15(2), 157. https://doi.org/10.3390/biom15020157
Feng, G., Wu, Y., Hu, Y., Shuai, W., Yang, X., Li, Y., Ouyang, L., & Wang, G. (2024). Small molecule inhibitors targeting m6A regulators. Journal of Hematology & Oncology, 17(1), 30.
Fiorentino, F., Menna, M., Rotili, D., Valente, S., & Mai, A. (2023). METTL3 from target validation to the first small-molecule inhibitors: A medicinal chemistry journey. Journal of Medicinal Chemistry, 66(3), 1654–1677. https://doi.org/10.1021/acs.jmedchem.2c01601
Gao, Z., Zha, X., Li, M., Xia, X., & Wang, S. (2024). Insights into the m6A demethylases FTO and ALKBH5: Structural, biological function, and inhibitor development. Cell & Bioscience, 14(1), 108.
Gu, X., Wang, L., Zhou, Y., Hu, X., Zhou, J., & Yan, C. (2021). NOP2/NSUN family: Key regulators in RNA methylation and cancer. Frontiers in Oncology, 11, 614640.
Guan, J. (2024). Oncogenic role of METTL3-mediated m6A modification in cancer. Molecular Cancer, 23(1), 12.
Guo, Q., Shi, X., & Wang, X. (2021). RNA and liquid-liquid phase separation. Noncoding RNA Research, 6(2), 92–99.
Han, D., Liu, J., Chen, C., Dong, L., Liu, Y., Chang, R., & He, C. (2023). Anti-tumour immunity controlled through mRNA m5C methylation and YBX1. Nature, 615(7953), 564–571.
Höfler, S., & Duss, O. (2024). Interconnections between m6A RNA modification, RNA structure, and protein-RNA complex assembly. Life Science Alliance, 7(1), e202302240. https://doi.org/10.26508/lsa.202302240
Huang, H., Weng, H., & Chen, J. (2020). m6A modification in coding and non-coding RNAs: Roles and therapeutic implications in cancer. Cancer Cell, 37(3), 270–288.
Huang, W., Qi, C., & Zhang, H. (2019). The emerging role of N1-methyladenosine (m1A) in post-transcriptional regulation. Cell & Bioscience, 9(1), 1–11.
Huang, Y., Su, R., Sheng, Y., Dong, L., Dong, Z., Xu, H., Ni, T., Zhang, Z. S., Zhang, T., Li, C., Han, L., Zhu, Z., Lian, F., Wei, J., Deng, Q., Wang, Y., Wunderlich, M., Gao, Z., Pan, G., ... Yang, C.-G. (2019). Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell, 35(4), 677–691.e10. https://doi.org/10.1016/j.ccell.2019.03.006
Jurkowska, R. Z. (2024). Chromatin regulation by histone-modifying complexes. Trends in Biochemical Sciences, 49(1), 1–14.
Katrekar, D., Yen, J., Xiang, Y., & Mali, P. (2022). Efficient in vitro and in vivo RNA editing via recruitment of endogenous ADARs using circular guide RNAs. Nature Biotechnology, 40(6), 938–945. https://doi.org/10.1038/s41587-021-01171-4
Lai, G. Q., Li, Y., Zhu, H., Zhang, T., Gao, J., Zhou, H., & Yang, C.-G. (2024). A covalent compound selectively inhibits RNA demethylase ALKBH5 rather than FTO. RSC Chemical Biology, 5(4), 335–343.
Li, M., Cheng, W., Zhang, L., Zhou, C., Peng, X., Yu, S., & Zhang, W. (2022). Novel roles of RNA m6A methylation regulators in the occurrence of Alzheimer’s disease and the subtype classification. International Journal of Molecular Sciences, 23(18), 10766.
Li, T., Hu, P., & Chen, X. (2021). Silencing METTL3 attenuates cardiac fibrosis after myocardial infarction. FASEB Journal, 35(2), e21257.
Li, W., Sun, R., & Zhou, X. (2025). METTL3-mediated m6A methylation promotes EMT and metastasis in cancer. Journal of Experimental & Clinical Cancer Research, 44(1), 15.
Li, Y., Bedi, R. K., Nai, F., von Roten, V., Dolbois, A., Zalešák, F., Nachawati, R., Huang, D., & Caflisch, A. (2022). Structure-based design of ligands of the m6A-RNA reader YTHDC1. European Journal of Medicinal Chemistry Reports, 5, 100057.
Liang, Y., Han, H., Liu, L., Duan, T., Zhao, Y., Xu, Q., & Chen, Y. (2024). m6A reader proteins in RNA metabolism, disease, and therapeutics. Pharmacology & Therapeutics, 250, 108478.
Liu, L., Qiu, Y., Suo, Y., Tong, S., Wang, Y., Zhang, X., Chen, L., Huang, Y., Zhou, H., Zhou, H., Dong, Z., & Yang, C.-G. (2024). Discovery of a potent PROTAC degrader for RNA demethylase FTO as antileukemic therapy. Acta Pharmaceutica Sinica B, 14(12), 5382–5392.
Liu, M., Wang, Y., Zhang, Y., Hu, D., Tang, L., Zhou, B., & Yang, L. (2025). Landscape of small nucleic acid therapeutics: Moving from the bench to the clinic as next-generation medicines. Signal Transduction and Targeted Therapy, 10(1), 73. https://doi.org/10.1038/s41392-024-02112-8
Liu, X. M., Zhou, J., Mao, Y., Ji, Q., Qian, S. B., & Shi, H. (2019). Programmable RNA N6-methyladenosine editing by CRISPR-Cas9 conjugates. Nature Chemical Biology, 15(9), 865–871. https://doi.org/10.1038/s41589-019-0327-1
Liu, Y., Li, X., Zhou, B., Zhang, X., & Zhao, Y. (2024). The role of pseudouridylation in mRNA translation and stability. RNA Biology, 21(1), 1–14.
Liu, Y., Wang, J., Zhang, Z., Chen, H., & Xu, Y. (2025). N6-methyladenosine modification regulates oxidative stress and inflammation in intervertebral disc degeneration. Frontiers in Cell and Developmental Biology, 13, 1547265.
Liu, Z., Gao, L., Cheng, L., Zhang, Y., Chen, L., & Zhu, W. (2023). The roles of N6-methyladenosine and its target regulatory noncoding RNAs in tumors: Classification, mechanisms, and potential therapeutic implications. Experimental & Molecular Medicine, 55, 487–501.
Lv, J., Zhang, Y., Gao, Y., Xu, S., Zhang, H., & Deng, J. (2021). METTL3-mediated m6A modification regulates Treg cell stability and suppressive function. Journal of Autoimmunity, 117, 102576.
Martin, R. L., Heifetz, A., Bodkin, M. J., & Townsend-Nicholson, A. (2024). High-throughput structure-based drug design (HT-SBDD) using drug docking, fragment molecular orbital calculations, and molecular dynamic techniques. In Methods in Molecular Biology (Vol. 2716, pp. 293–306). Springer. https://doi.org/10.1007/978-1-0716-3449-3_13
Mendel, M., Chen, K. M., Homolka, D., Gos, P., Pandey, R. R., McCarthy, A. A., & Pillai, R. S. (2021). Splice site m6A methylation prevents binding of U2AF35 to inhibit RNA splicing. Nature, 598(7882), 332–336.
Nossent, A. Y., Liu, L., Hansen, T. B., & Kjems, J. (2023). The emerging role of m6A in cardiovascular biology and disease. Cardiovascular Research, 119(2), 326–341.
Ouyang, H., Chen, Z., & Wang, J. (2024). METTL3-mediated m6A methylation enhances metastasis via stabilization of ZEB1 and SNAIL mRNAs. Cell Death & Disease, 15, 142.
Padda, I. S., Kalra, I., & Kalagara, R. (2024). Small interfering RNA therapeutics. StatPearls Publishing.
Paramasivam, A., Priyadharsini, J. V., & Raghunandhakumar, S. (2020). Implications of m6A modification in autoimmune disorders. Molecular Biology Reports, 47, 9267–9275.
Park, C. W., Lee, S. M., & Yoon, K. J. (2020). Epitranscriptomic regulation of transcriptome plasticity in development and diseases of the brain. BMB Reports, 53(11), 551–564.
Pickar-Oliver, A., & Gersbach, C. A. (2019). The next generation of CRISPR-Cas technologies and applications. Nature Reviews Molecular Cell Biology, 20, 490–507.
Qin, Y., Liu, X., Pan, Y., & Liu, J. (2022). The m6A-modified circular RNAs in cancer progression: Roles, mechanisms, and potential applications. Frontiers in Oncology, 12, 891276.
Qui, Y., Xu, Z., Zhang, X., & Zhou, L. (2023). Epitranscriptomic regulation of gene expression: Focus on m6A and m5C. Cellular and Molecular Life Sciences, 80(1), 1–21.
Rau, K., Rentmeister, A., & Reimann, R. (2019). Sequence-specific m6A demethylation in RNA by FTO fused to RCas9. RNA, 25(10), 1311–1323.
Shen, D., Wang, B., Gao, Y., Zhao, L., Bi, Y., Zhang, J., Wang, N., Kang, H., Pang, J., Liu, Y., Pang, L., Chen, Z.-S., Zheng, Y.-C., & Liu, H.-M. (2022). Detailed resume of RNA m6A demethylases. Acta Pharmaceutica Sinica B, 12(5), 2193–2205. https://doi.org/10.1016/j.apsb.2022.01.003
Shi, H., Wei, J., & He, C. (2020). Where, when, and how: Context-dependent functions of RNA methylation writers, readers, and erasers. Molecular Cell, 78(1), 1–16.
Song, H., Zhang, J., Liu, B., Xu, J., Cai, B., Yang, H., Straube, J., Yu, X., & Ma, T. (2022). Biological roles of RNA m5C modification and its implications in cancer immunotherapy. Biomarker Research, 10(1), 15.
Song, J., Zong, J., Yu, Y.-T., & Li, X. (2023). CRISPR-free, programmable RNA pseudouridylation to suppress premature termination codons. Molecular Cell, 83(1), 139–155.e9. https://doi.org/10.1016/j.molcel.2022.11.011
Su, R., Dong, L., Li, Y., Gao, M., Han, L., Wunderlich, M., Deng, X., Li, H., Huang, Y., Gao, L., Li, C., Zhao, Z., Robinson, S., Tan, B., Qing, Y., Qin, X., Prince, E., Xie, J., Qin, H., Li, W., ... Chen, J. (2020). Targeting FTO suppresses cancer stem cell maintenance and immune evasion. Cancer Cell, 38(1), 79–96.e11.
Sun, T., Wu, R., & Ming, L. (2023). The role of m6A RNA methylation in cancer metabolism. Molecular Cancer, 22(1), 1–16.
Sweef, M., Alshahrani, M., & Wang, W. (2024). N1-methyladenosine (m1A) modification in human diseases. Frontiers in Molecular Biosciences, 11, 1304567.
Thalhammer, A., Bencokova, Z., Poole, R., Loenarz, C., Adam, J., O'Flaherty, L., & Pollard, P. J. (2011). Human AlkB homologue 5 is a nuclear 2-oxoglutarate dependent oxygenase and a direct target of hypoxia-inducible factor-1α (HIF-1α). PLoS ONE, 6(1), e16210.
Tooley, J. G., Catlin, J. P., & Schaner Tooley, C. E. (2023). METTLing in stem cell and cancer biology. Stem Cell Reviews and Reports, 19(1), 76–91. https://doi.org/10.1007/s12015-022-10444-7
U.S. Food and Drug Administration. (2018, August 14). New class of drugs fulfills promise of RNA-based medicine. https://www.fda.gov/drugs/spotlight-cder-science/new-class-drugs-fulfills-promise-rna-based-medicine
Wang, J., Yan, S., Lu, H., Wang, S., Xu, D., & Xu, Z. (2021). Role of m6A RNA methylation in immunoregulation and autoimmunity. Frontiers in Cell and Developmental Biology, 9, 757677.
Wang, X., Li, Z., & Zhang, Y. (2024). m1A RNA modification: Mechanisms, functions, and disease relevance. RNA Biology, 21(2), 200–214.
Wang, X., Ma, X., Chen, S., Fan, M., Jin, C., Chen, Y., Wang, S., Wang, Z., Meng, F., Zhang, C., & Yang, L. (2024). Harnessing m1A modification: A new frontier in cancer immunotherapy. Frontiers in Immunology, 15, 1517604. https://doi.org/10.3389/fimmu.2024.1517604
Wang, X., Zhao, B. S., Roundtree, I. A., Lu, Z., Han, D., Ma, H., & He, C. (2015). N6-methyladenosine modulates messenger RNA translation efficiency. Cell, 161(6), 1388–1399.
Wen, J., Lv, R., Ma, H., Shen, H., He, C., Wang, J., & Shi, Y. (2024). YTHDF1 regulates dendritic cell-mediated immune response via m6A-dependent translation of immune transcripts. Nature Communications, 15, 1124.
Wilkinson, A., Ji, D., Papa, F., & Schaefer, M. (2022). The dynamic life of m6A RNA modification. Nature Reviews Genetics, 23(8), 499–512.
Wilkinson, J., Thalhammer, A., Loenarz, C., & Schofield, C. J. (2021). Regulation of the ALKBH5 RNA demethylase in hypoxia. Biochemical Journal, 478(7), 1483–1501.
Wilson, C., Chen, P. J., Miao, Z., & Liu, D. R. (2020). Programmable m6A modification of cellular RNAs with a Cas13-directed methyltransferase. Nature Biotechnology, 38(12), 1431–1440. https://doi.org/10.1038/s41587-020-0572-6
Wong, J. M., & Eirin-Lopez, J. M. (2021). Evolution of methyltransferase-like (METTL) proteins in Metazoa: A complex gene family involved in epitranscriptomic regulation and other epigenetic processes. Molecular Biology and Evolution, 38(12), 5309–5327.
Xia, Z., Tang, H., Wang, S., He, S., Zhang, L., & Chen, S. (2021). Epitranscriptomic editing of the RNA N6-methyladenosine modification by dCasRx conjugated methyltransferase and demethylase. Nucleic Acids Research, 49(13), 7361–7374. https://doi.org/10.1093/nar/gkab517
Xie, G., Wu, X.-N., Ling, Y., Rui, Y., Wu, D., Zhou, J., et al. (2022). A novel inhibitor of N6-methyladenosine demethylase FTO induces mRNA methylation and shows anti-cancer activities. Acta Pharmaceutica Sinica B, 12(2), 853–866. https://doi.org/10.1016/j.apsb.2021.08.028
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023). Recent advances in targeting the “undruggable” proteins: From drug discovery to clinical trials. Signal Transduction and Targeted Therapy, 8(1), 335. https://doi.org/10.1038/s41392-023-01589-z
Xiong, X., Li, X., & Yi, C. (2022). N1-methyladenosine methylome in eukaryotic messenger RNA and its biological implications. Nature Structural & Molecular Biology, 29(4), 271–280.
Xu, Y., Zhang, Y., & Zhang, J. (2022). Epigenetic regulation by histone modifications in cancer. Nature Reviews Cancer, 22(11), 671–686.
Xue, C., Zhao, Y., & Li, L. (2022). RNA methylation in plant and human biology. RNA Biology, 19(5), 569–583.
Yang, Y., Hsu, P. J., Chen, Y. S., & Yang, Y. G. (2022). Dynamic transcriptomic m6A decoration: Writers, erasers, readers and functions in RNA metabolism. Cell Research, 32(5), 499–516.
Yang, Y., Lu, Y., Wang, Y., Wen, X., Qi, C., Piao, W., & Jin, H. (2024). Current progress in strategies to profile transcriptomic m6A modifications. Frontiers in Cell and Developmental Biology, 12, 1392159.
Yao, Y., Yang, Y., Guo, W., Xu, L., You, M., Zhang, Y., & Han, J. (2021). METTL3-dependent m6A modification programs dendritic cell activation. Nature Communications, 12, 5826.
Ying, X., Jiang, X., Zhang, H., Liu, B., Huang, Y., & Zhang, H. (2020). Programmable N6-methyladenosine modification of CDCP1 mRNA by RCas9-methyltransferase-like 3 conjugates promotes bladder cancer development. Molecular Cancer, 19(1), 1–6.
Zhang, C., Samanta, D., Lu, H., Bullen, J. W., Zhang, H., Chen, I., & Semenza, G. L. (2016). Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA. Proceedings of the National Academy of Sciences of the United States of America, 113(14), E2047–E2056. https://doi.org/10.1073/pnas.1602883113
Zhang, J., Tong, L., Liu, Y., Li, X., Wang, J., Lin, R., Zhou, Z., Chen, Y., Chen, Y., Liu, Y., & Chen, D. (2023). The regulatory role of m6A modification in the maintenance and differentiation of embryonic stem cells. Genes & Diseases, 11(5), 101199.
Zhang, X., Li, H., & Chen, Y. (2021). m5C modification in RNA: Mechanisms and implications in human disease. Frontiers in Genetics, 12, 730682.
Zhang, X., Li, J., Zhou, X., Liu, Y., Wang, Z., & Li, L. (2024). METTL3 in immune regulation and autoimmune disease pathogenesis. Autoimmunity Reviews, 23, 103453.
Zhao, B. S., Wang, X., Beadell, A. V., Lu, Z., Shi, H., Kuuspalu, A., Ho, R. K., & He, C. (2017). m6A-dependent maternal mRNA clearance facilitates zebrafish maternal-to-zygotic transition. Nature, 542(7642), 475–478. https://doi.org/10.1038/nature21355
Zhao, F., Xu, Y., Gao, S., Qin, L., Austria, Q., Siedlak, S. L., Pajdzik, K., Dai, Q., He, C., Wang, W., O'Donnell, J. M., Tang, B., & Zhu, X. (2021). METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer’s disease through aberrant cell cycle events. Molecular Neurodegeneration, 16(1), 70. https://doi.org/10.1186/s13024-021-00484-x
Zhao, Y., Dunker, W., Yu, Y.-T., & Karijolich, J. (2018). The role of noncoding RNA pseudouridylation in nuclear gene expression events. Frontiers in Bioengineering and Biotechnology, 6, 8. https://doi.org/10.3389/fbioe.2018.00008
Zhao, Y., Wang, X., & Li, X. (2025). Pseudouridine and its functional implications in RNA biology. Trends in Biochemical Sciences, 50(1), 12–25.
Zou, J., Guo, Y., Zhao, Y., Pan, W., Xu, J., & Su, S. (2024). N6-methyladenosine modification of SARS-CoV-2 RNA facilitates immune evasion and viral replication. Cell Reports, 42, 113452.